Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.69 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.69 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.62 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.62 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.62 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.55 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HRH1 | P35367 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5115281 | 0.90 | CHRNB2 (0.65) | CHRNB2CHRNA4PRMT6CARM1PRMT8 | |
| SCHEMBL10028665 | 0.85 | CHRNB2 (0.85) | CHRNB2CHRNA4CHRNA7KDM4EALDH1A1 | |
| SCHEMBL16627431 | 0.84 | CHRNB2 (0.77) | CHRNB2CHRNA4CHRNA7KDM4EALDH1A1 | |
| SCHEMBL4868554 | 0.84 | PRMT6 (0.60) | CHRNB2CHRNA4PRMT6CARM1PRMT8 | |
| SCHEMBL9827841 | 0.83 | CHRNB2 (0.69) | CHRNB2CHRNA4CHRNA7KDM4EALDH1A1 | |
| SCHEMBL27928441 | 0.82 | CHRNA7 (0.58) | CHRNB2CHRNA4CHRNA7CYP2A6HRH1 | |
| SCHEMBL31044635 | 0.82 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7KDM4EALDH1A1 | |
| SCHEMBL6674571 | 0.82 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7KDM4EALDH1A1 | |
| SCHEMBL30093157 | 0.82 | CHRNB2 (0.79) | CHRNB2CHRNA4CHRNA7KDM4EALDH1A1 | |
| SCHEMBL11922687 | 0.81 | CHRNB2 (0.72) | CHRNB2CHRNA4CHRNA7KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7332476-B2 | Pyridyl substituted ketolide antibiotics | NOVARTIS AG (CH) | 2008-02-19 | — | — | US | disclosed |
| US-6756359-B2 | ADMINISTERING A 14 MEMBERED MACROLIDE AND KETOLIDE ANTIBIOTICS CONTAINING C12 MODIFICATIONS TO A PATIENT SUFFERING FROM BACTERIAL INFECTIONS | CHIRON CORPORATION | 2004-06-29 | — | — | US | disclosed |
| US-20030125266-A1 | C12 Modified erythromycin macrolides and ketolides having antibacterial activity | CHU DANIEL (US) | 2003-07-03 | — | — | US | disclosed |
| US-6191118-B1 | ANTIBIOTICS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2001-02-20 | — | — | US | disclosed |
| EP-0945459-A1 | ERYTHROMYCIN A DERIVATIVES | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1999-09-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125266-A1 | C12 Modified erythromycin macrolides and ketolides having antibacterial activity | MRPL21, CYP51A1, CEL | CHRNB2 4844/4885CHRNA4 4882/4885PRMT6 3551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.